ASCO 2024 | Highlights in skin cancer at ASCO 2024
Georgina Long, PhD, MBBS, FRACP, FAHMS, University of Sydney, North Sydney, Australia, shares findings from the NADINA trial (NCT04949113), the first Phase III trial that evaluates neoadjuvant immunotherapy against standard of care in melanoma, and the first Phase III trial in oncology evaluating a neoadjuvant regimen consisting of immunotherapy alone. Neoadjuvant nivolumab and ipilimumab followed by response-driven adjuvant treatment results in statistically significant improved event-free survival compared to adjuvant nivolumab and should be considered a new standard of care treatment in macroscopic stage III melanoma. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria – BMS; Pierre Fabre
Consulting or Advisory Role – Agenus; Amgen; Array BioPharma; AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb; Evaxion Biotech; Hexal; Highlight Therapeutics; Immunocore Ireland Limited; Innovent Biologics; IO Biotech; Merck Sharp & Dohme; Novartis; OncoSec; PHMR; Pierre Fabre; Regeneron
